

WEEKLY EPIDEMIOLOGICAL REPORT

A publication of the Epidemiology Unit Ministry of Health

231, de Saram Place, Colombo 01000, Sri Lanka
Tele: + 94 11 2695112, Fax: +94 11 2696583, E mail: epidunit@sltnet.lk
Epidemiologist: +94 11 2681548, E mail: chepid@sltnet.lk
Web: http://www.epid.gov.lk

Vol. 42 No. 17

18th – 24th April 2015

Malaria (Part III)

This is the final article of the series of articles on Malaria

Surveillance

Tracking progress is a major challenge in malaria control. In 2012, malaria surveillance systems detected only around 14% of the estimated global number of cases. Stronger malaria surveillance systems are urgently needed to enable a timely and effective malaria response in endemic regions, to prevent outbreaks and resurgences, to track progress, and to hold governments and the global malaria community accountable.

Elimination

Malaria elimination is defined as interrupting local mosquito-borne malaria transmission in a defined geographical area, i.e. zero incidence of locally contracted cases. Malaria eradication is defined as the permanent reduction to zero of the worldwide incidence of malaria infection caused by a specific agent; i.e. applies to a particular malaria parasite species.

On the basis of reported cases for 2013, 55 countries are on track to reduce their malaria case incidence rates by 75%, in line with World Health Assembly targets for 2015. Large-scale use of WHO-recommended strategies, currently available tools, strong national commitments, and coordinated efforts with partners, will enable more countries – particularly those where malaria transmission is low and unstable – to re-

duce their disease burden and progress towards elimination.

In recent years, 4 countries have been certified by the WHO Director-General as having eliminated malaria: United Arab Emirates (2007), Morocco (2010), Turkmenistan (2010) and Armenia (2011).

Vaccines against malaria

There are currently no licensed vaccines against malaria or any other human parasite. One research vaccine against *P. falciparum*, known as RTS, S/AS01, is the most advanced. This vaccine has been evaluated in a large clinical trial in 7 countries in Africa and has been submitted to the European Medicines Agency under art. 58 for regulatory review. A WHO recommendation for use will depend on the final results from the large clinical trial and a positive regulatory review. The recommendation as to whether or not this vaccine should be added to existing malaria control tools is expected in late 2015.

WHO response

The WHO Global Malaria Programme (GMP) is responsible for charting the course for malaria control and elimination through

- setting, communicating and promoting the adoption of evidence-based norms, standards, policies, technical strategies, and guidelines
- keeping independent score of global progress

Contents	Page
1. Leading Article – Malaria -(Part III)	1
2. Summary of selected notifiable diseases reported - (11th - 17th April 2015)	3
3. Surveillance of vaccine preventable diseases & AFP - (11th – 17th April 2015)	4

- developing approaches for capacity building, systems strengthening, and surveillance
- identifying threats to malaria control and elimination as well as new areas for action.

GMP serves as the secretariat for the Malaria Policy Advisory Committee (MPAC), a group of 15 global malaria experts appointed following an open nomination process. The MPAC, which meets twice yearly, provides independent advice to WHO to develop policy recommendations for the control and elimination of malaria. The mandate of MPAC is to provide strategic advice and technical input, and extends to all aspects of malaria control and elimination, as part of a transparent, responsive and credible policy setting process.

WHO is also a co-founder and host of the Roll Back Malaria partnership, which is the global framework to implement coordinated action against malaria. The partnership mobilizes for action and resources and forges consensus among partners. It is comprised of over 500 partners, including malaria endemic countries, development partners, the private sector, nongovernmental and community-based organizations, foundations, and research and academic institutions.

Response in Sri Lanka

Anti Malaria Campaign was established in 1911, and the campaign has been responsible for the control of the disease in the country. Currently the Anti Malaria Campaign, the equivalent of the National Malaria Control Programme, is a specialized campaign of the Ministry of Health and comprises the Directorate and twenty district-level Regional Offices. It functions as a decentralized campaign, the Directorate coming under the purview of the Line Ministry of Health (Central Ministry) and the Regional Offices belonging to the nine Provincial Health Administrations.




Table 1-Number of Malaria cases in Sri Lanka 2000-2013

Sources:

Malaria, available at http://www.who.int/mediacentre/factsheets/fs094/en/

Current Malaria Situation, available at http://www.malariacampaign.gov.lk/

Compiled by Dr. C U D Gunasekara of the Epidemiology Unit

Table 1 : Water Quality Surveillance Number of microbiological water samples March/ 2015

District	MOH areas	No: Expected *	No: Received
Colombo	12	72	90
Gampaha	15	90	82
Kalutara	12	72	NR
Kalutara NIHS	2	12	16
Kandy	23	138	NR
Matale	12	72	3
Nuwara Eliya	13	78	8
Galle	19	114	NR
Matara	17	102	25
Hambantota	12	72	49
Jaffna	11	66	22
Kilinochchi	4	24	0
Manner	5	30	0
Vavuniya	4	24	15
Mullatvu	4	24	22
Batticaloa	14	84	0
Ampara	7	42	34
Trincomalee	11	66	6
Kurunegala	23	138	111
Puttalam	9	54	6
Anuradhapura	19	114	NR
Polonnaruwa	7	42	0
Badulla	15	90	76
Moneragala	11	66	53
Rathnapura	18	108	22
Kegalle	11	66	59
Kalmunai	13	78	0

^{*} No of samples expected (6 / MOH area / Month) NR = Return not received

Table 1: Selected notifiable diseases reported by Medical Officers of Health 11th - 17th April 2015 (16th Week)

													•												•		•		•
8	*	19	20	0	26	23	15	100	0	0	œ	20	0	20	9	21	14	17	22	38	11	59	24	6	17	27	54	25	
WRCD	*_	81	80	100	74	77	85	0	100	100	92	20	100	20	40	79	98	83	78	62	89	71	9/	91	83	73	46	75	
Leishmani- asis	В	0	0	0	1	က	0	0	91	22	0	0	0	н	ო	0	0	1	32	1	85	45	2	10	4	0	0	301	
Leish asis	⋖	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0	1	4	0	1	0	0	0	œ	
gitis	В	14	8	14	4	ю	18	13	4	6	9	0	0	က	2	10	т	2	7	6	12	11	22	5	12	19	4	214	
Meningitis	4	0	0	0	0	П	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	4	0	9	eness
Chickenpox	В	181	64	105	90	7	25	09	41	89	81	10	2	32	1	15	85	32	160	28	77	49	49	33	39	78	49	1482	number of reporting units 337 Number of reporting units data provided for the current week: 257 C**- Completeness
Chick	⋖	10	2	4	1	0	П	0	9	2	11	0	7	0	0	7	н	2	4	0	1	0	2	0	1	7	0	27	257 C**
nan ies	В	Э	0	н	0	0	0	0	0	0	Н	н	0	н	0	0	0	П	П	0	0	0	7	П	0	0	0	12	t week:
Human Rabies	∢	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	эе сигге
Viral Hepatitis	В	15	29	13	29	18	36	4	17	11	7	0	0	H	7	0	7	9	15	1	8	က	22	26	119	46	0	539	ovided for th
	⋖	0	∞	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	∞	7	0	М	0	24	data pro
Typhus Fever	В	က	9	0	25	4	29	22	18	17	463	∞	15	11	9	0	0	Э	13	7	14	П	36	29	24	22	0	776	orting units
Тур	∢	П	0	0	0	0	Н	0	н	0	4	0	0	0	0	0	0	0	0	0	П	0	0	7	0	н	0	#	er of rep
Leptospirosi s	В	90	166	112	25	20	10	22	32	73	10		∞	10	က	2	9	11	95	17	115	39	23	96	118	94	7	1233	337 Numb
Lep	∢	П	7	н	7	н	0	0	0	П	Н	0	0	0	0	0	0	0	П	0	က	0	0	က	П	9	0	28	ing units
Food Poisoning	В	48	10	65	က	т	0	9	4	44	28	22	н	Μ	н	97	7	23	10	9	48	0	9	2	н	ю	70	459	er of report
_ P	∢	0	0	0	н	0	0	0	0	0	0	0	0	0	0	7	0	1	0	0	0	0	н	0	0	0	H	9	
Enteric Fever	В	27	8	14	13	4	6	7	4	4	126	က	4	22	4	10	н	15	3	1	2	9	3	8	21	34	н	352	ii , 2015 Tot
	∢	0	П	0	0	0	н	0	0	0	4	0	0	н	0	7	0	0	0	0	0	0	0	0	0	0	0	0	17 th Apr
Encephalit is	В	4	κ	4	4	0	Н	0	0	κ	œ	0	0	4	7	4	0	0	7	2		2	т	П	κ	7	0	28	or before
Enc	∢	0	0	0	0	0	0	0	0	0	Н	0	0	0	0	0	0	0	0	0	0	0	0	0	0	н	0	7	(D) .
Dysentery	В	65	23	34	46	21	96	24	11	27	227	34	4	10	10	107	18	17	61	13	24	22	49	40	105	30	44	1162	ases (WRC eturns recei
Q	∢	3	П	н	н	0	н	0	0	0	6	7	0	0	0	ო	н	0	3	0	н	0	0	7	2	0	н	31	e Dise
Dengue Fever	В	3614	1673	909	539	292	9/	283	139	192	982	32	89	57	29	957	20	343	648	379	239	109	298	92	401	221	348	12675	f Communicable Diseases (WRCD). •T=Timeliness refers to returns received on or before 17th April , 2015 Total
Deng	⋖	26	28	11	12	1	0	0	ю	7	13	0	0	П	m	18	0	6	7	2	1	0	0	2	4	2	П	184	eturns of (
RDHS Division		Colombo	Gampaha	Kalutara	Kandy	Matale	NuwaraEliya	Galle	Hambantota	Matara	Jaffna	Kilinochchi	Mannar	Vavuniya	Mullaitivu	Batticaloa	Ampara	Trincomalee	Kurunegala	Puttalam	Anuradhapura	Polonnaruwa	Badulla	Monaragala	Ratnapura	Kegalle	Kalmune	SRILANKA	Source: Weekly Returns of Communicable Diseases (WRCD) 'T=Timeliness refers to returns received

Table 2: Vaccine-Preventable Diseases & AFP

11th - 17th April 2015 (16th Week)

Disease			N	lo. of Cas	es by P	rovince			Number of cases during current	Number of cases during same	Total number of cases to date in	Total num- ber of cases to date in	Difference between the number of cases to date		
	W	С	S	N	Е	NW	NC	U	Sab	week in 2015	week in 2014	2015	2014	in 2014& 2015	
AFP*	00	02	00	00	00	00	00	00	00	02	01	22	26	-15.3%	
Diphtheria	00	00	00	00	00	00	00	00	00	00	00	00	00	%	
Mumps	01	00	00	00	01	00	00	01	00	03	06	118	241	-51.0%	
Measles	12	04	05	01	01	01	04	02	00	30	25	655	1418	-53.8%	
Rubella	00	00	00	00	00	00	00	00	00	00	01	04	08	-50%	
CRS**	00	00	00	00	00	00	00	00	00	00	00	00	03	%	
Tetanus	00	00	00	00	00	00	00	00	00	00	00	04	06	-33.3%	
Japanese En- cephalitis	00	00	00	00	00	00	00	00	01	01	00	07	17	-59.1%	
Neonatal Teta- nus	00	00	00	00	00	00	00	00	00	00	00	00	00	%	
Whooping Cough	01	00	00	00	00	00	00	00	00	01	00	30	19	58.1%	
Tuberculosis	21	12	31	02	01	31	03	00	27	128	64	2816	3152	-89.3%	

Key to Table 1 & 2

Provinces: W: Western, C: Central, S: Southern, N: North, E: East, NC: North Central, NW: North Western, U: Uva, Sab: Sabaragamuwa.

RDHS Divisions: CB: Colombo, GM: Gampaha, KL: Kalutara, KD: Kandy, ML: Matale, NE: Nuwara Eliya, GL: Galle, HB: Hambantota, MT: Matara, JF: Jaffna,

KN: Killinochchi, MN: Mannar, VA: Vavuniya, MU: Mullaitivu, BT: Batticaloa, AM: Ampara, TR: Trincomalee, KM: Kalmunai, KR: Kurunegala, PU: Puttalam,

AP: Anuradhapura, PO: Polonnaruwa, BD: Badulla, MO: Moneragala, RP: Ratnapura, KG: Kegalle.

Data Sources:

Weekly Return of Communicable Diseases: Diphtheria, Measles, Tetanus, Neonatal Tetanus, Whooping Cough, Chickenpox, Meningitis, Mumps., Rubella, CRS,

Special Surveillance: AFP* (Acute Flaccid Paralysis), Japanese Encephalitis

CRS** =Congenital Rubella Syndrome

AFP and all clinically confirmed Vaccine Preventable Diseases except Tuberculosis and Mumps should be investigated by the MOH

	Influenza Surveill	za Surveillance in Sentinel Hospitals - ILI & SARI														
	Month	Human			Animal											
		No Received	ILI	SARI	Infl A	Infl B	Pooled samples	Serum Samples	Positives							
	March	3935	111	19	7	11	1023	352	0							

Source: Medical Research Institute & Veterinary Research Institute

PRINTING OF THIS PUBLICATION IS FUNDED BY THE WORLD HEALTH ORGANIZATION (WHO).

Comments and contributions for publication in the WER Sri Lanka are welcome. However, the editor reserves the right to accept or reject items for publication. All correspondence should be mailed to The Editor, WER Sri Lanka, Epidemiological Unit, P.O. Box 1567, Colombo or sent by E-mail to chepid@sltnet.lk. Prior approval should be obtained from the Epidemiology Unit before publishing data in this publication

ON STATE SERVICE